Bevacizumab-800CW: A Comprehensive Analysis of a Targeted Fluorescent Imaging Agent in Precision Oncology

Executive Summary

Bevacizumab-800CW is an investigational immunoconjugate poised to redefine the landscape of surgical and endoscopic oncology. This agent is meticulously engineered by conjugating bevacizumab, a well-established recombinant humanized monoclonal antibody targeting Vascular Endothelial Growth Factor-A (VEGF-A), with IRDye 800CW, a high-performance near-infrared (NIR) fluorophore.[1] By targeting the fundamental process of angiogenesis, a hallmark of solid tumors, bevacizumab-800CW functions as a high-specificity molecular imaging probe. Its core purpose is to provide clinicians with real-time, high-contrast visualization of malignant tissue, thereby addressing critical unmet needs in cancer surgery and diagnosis.

The foundational thesis of this report is that bevacizumab-800CW represents a paradigm shift from non-specific, passive imaging techniques to active, molecularly targeted visualization. Preclinical and early-phase clinical studies have consistently demonstrated its excellent safety profile when administered in sub-therapeutic microdoses. More importantly, these trials have established its superior efficacy compared to conventional, non-targeted fluorescent agents such as Indocyanine Green (ICG). Key performance metrics, including significantly higher tumor-to-background ratios and markedly lower false-positive rates, underscore its potential.[3] This superiority is particularly pronounced in clinically challenging scenarios, such as identifying residual tumor nodules after neoadjuvant chemotherapy, where non-specific agents often fail due to confounding signals from inflammation and altered vasculature.[3]

The major implication of the existing body of evidence is that bevacizumab-800CW is a significant technological advancement toward achieving more precise and complete tumor resections. Its demonstrated utility in improving the assessment of surgical margins, enhancing the detection of occult metastases, and identifying early-stage neoplastic lesions suggests broad applicability across a multitude of cancer types, including breast, colorectal, esophageal, and central nervous system malignancies.[5] As this agent progresses through clinical development, it holds the promise of transforming surgical and endoscopic procedures from anatomically-guided interventions to molecularly-informed, high-precision therapies.

Section 1: Molecular Profile and Pharmaceutical Characteristics

The design of bevacizumab-800CW is a deliberate exercise in molecular engineering, combining a clinically validated targeting vehicle with a state-of-the-art imaging payload. Understanding its efficacy requires a deconstruction of its constituent parts—the antibody and the fluorophore—and an appreciation for the rigorous process of synthesizing and formulating the final clinical-grade immunoconjugate.

1.1 The Targeting Moiety: Bevacizumab as a VEGF-A Antagonist

The foundation of bevacizumab-800CW's specificity is the monoclonal antibody bevacizumab. Bevacizumab is a recombinant, humanized monoclonal antibody of the IgG1 isotype, produced in Chinese Hamster Ovary (CHO) cell lines.[8] It is the active pharmaceutical ingredient in the globally recognized therapeutic drug Avastin® and its growing list of approved biosimilars, including Mvasi®, Zirabev®, and Alymsys®.[8]

The antibody's biological target is human Vascular Endothelial Growth Factor-A (VEGF-A), a pivotal pro-angiogenic cytokine.[8] Bevacizumab binds with high affinity to and neutralizes all known isoforms and bioactive proteolytic fragments of VEGF-A.[5] Angiogenesis, the formation of new blood vessels, is a fundamental process required for tumors to grow beyond a few millimeters, and VEGF-A is a master regulator of this process. Its expression is frequently upregulated in a vast array of solid tumors, correlating not only with microvessel density but also with poor clinical prognosis.[5]

The selection of bevacizumab as the targeting moiety for an imaging agent is therefore highly strategic. Because VEGF-A is a near-universal feature of solid tumors, with an expression rate of approximately 73% in breast cancer compared to normal tissue, it serves as a generic and broadly applicable target.[5] This allows bevacizumab-800CW to be potentially used across many cancer types without the need for patient pre-selection based on less common biomarkers, such as the human epidermal growth factor receptor 2 (HER2), which is overexpressed in only 10% to 20% of primary breast cancers.[5] The high affinity and specificity of bevacizumab for VEGF-A provide a robust and reliable foundation for a targeted imaging agent designed for widespread oncological application.

1.2 The Imaging Moiety: Physicochemical Properties of IRDye 800CW

The visualization component of the immunoconjugate is IRDye 800CW, a sophisticated near-infrared (NIR) fluorescent dye. This fluorophore is specifically designed for in vivo imaging applications, with a peak absorption maximum (λabs​) around 773-778 nm and a peak emission maximum (λem​) around 791-795 nm.[17]

From a chemical standpoint, IRDye 800CW is a hydrophilic molecule, a property that improves its solubility and pharmacokinetic behavior.[19] Its molecular weight is approximately 1166.2 g/mol for the NHS ester form, with a chemical formula of

C50​H54​N3​Na3​O17​S4​.[20] For clinical use, it is most commonly supplied with an N-hydroxysuccinimide (NHS) ester reactive group. This functional group allows for efficient and stable covalent conjugation to primary and secondary amines, such as the abundant lysine residues present on the surface of antibodies like bevacizumab, forming a durable amide bond.[1]

The optical properties of IRDye 800CW confer a significant advantage for biological imaging. The 700-1,000 nm spectral window, often referred to as the "NIR window," is optimal for deep-tissue imaging because it minimizes the confounding effects of light absorption by endogenous chromophores like hemoglobin and water, and it reduces tissue autofluorescence, which is a major source of background noise at lower (visible) wavelengths.[2] This results in superior tissue penetration and a higher signal-to-noise ratio, enabling the detection of fluorescent signals from deeper within the body compared to visible-light fluorophores.

1.3 The Immunoconjugate: Synthesis, Formulation, and Stability of Clinical-Grade Bevacizumab-800CW

The creation of a clinical-grade imaging agent from these two components is a highly controlled pharmaceutical process. The production of bevacizumab-800CW is conducted according to current Good Manufacturing Practice (GMP) guidelines to ensure its safety, purity, and consistency for human use.[17]

The synthesis involves the covalent labeling of the bevacizumab antibody with the NHS ester form of IRDye 800CW. This reaction is performed in a buffered solution (e.g., phosphate-buffered saline at pH 8.5) with a carefully controlled dye-to-protein (D:P) molar ratio, typically ranging from 2:1 to 4:1, to achieve optimal labeling without compromising the antibody's function.[17] After the conjugation reaction, the product undergoes a rigorous purification process, often using size-exclusion high-performance liquid chromatography (SE-HPLC), to remove any unconjugated free dye and to assess the purity and integrity of the final immunoconjugate.[17]

The purified bevacizumab-800CW is then formulated into a sterile, isotonic phosphate-buffered sodium chloride solution at a physiological pH of 7, typically at a concentration of 1 mg/mL, and filled into injection vials.[17] Extensive quality control tests are performed on the final product, including assessments of identity, chemical purity, endotoxin levels, and biological activity.[17] A critical quality attribute is the retention of binding affinity to VEGF-A, which has been confirmed to remain intact after the conjugation process.[25] The final formulated product has demonstrated stability for at least three months, ensuring it can be produced in stock for clinical trials and eventual clinical use.[25]

The combination of bevacizumab and IRDye 800CW is not merely an additive process but a synergistic one. The clinical challenge is the real-time, high-specificity visualization of tumors. To solve this, a target that is highly expressed in tumors but not in most healthy tissues is needed; VEGF-A, as a hallmark of angiogenesis, is an ideal candidate.[5] A high-affinity molecular probe is required to engage this target, and bevacizumab is a clinically validated antibody that fulfills this role perfectly.[8] Finally, a signal is needed that can be detected with high sensitivity and minimal background interference through biological tissue. NIR fluorescence in the 800 nm window provides this capability, and IRDye 800CW is a premier fluorophore in this spectrum with convenient chemistry for stable conjugation.[19] Thus, the high specificity of the antibody is leveraged by the high performance of the NIR dye to create an agent that is fundamentally designed to be superior to non-targeted agents like ICG or agents that operate in the less-penetrating visible spectrum.

Component	Property	Value / Description	Source
Bevacizumab	Class	Recombinant Humanized Monoclonal Antibody	8
	Isotype	IgG1	9
	Target	Vascular Endothelial Growth Factor-A (VEGF-A)	8
	Host Cells	Chinese Hamster Ovary (CHO)	9
	Reference Drug	Avastin®	8
IRDye 800CW (NHS Ester)	Chemical Formula	C50​H54​N3​Na3​O17​S4​	20
	Molecular Weight	1166.20 g/mol	20
	Absorbance Max (λabs​)	767-778 nm	18
	Emission Max (λem​)	791-795 nm	18

Section 2: Dual Mechanism of Action

The functionality of bevacizumab-800CW is rooted in a dual mechanism that combines targeted biological activity with advanced optical physics. The agent first leverages the pharmacodynamic properties of the bevacizumab antibody to achieve specific localization within the tumor microenvironment. Subsequently, it utilizes the photophysical properties of the IRDye 800CW fluorophore to generate a detectable signal, enabling real-time visualization.

2.1 Pharmacodynamic Action: Inhibition of Angiogenesis via VEGF-A Sequestration

The biological action of bevacizumab-800CW is identical to that of its parent antibody, bevacizumab. Upon administration, the bevacizumab moiety of the conjugate selectively binds with high affinity to all isoforms of circulating VEGF-A.[13] This binding action effectively sequesters the VEGF-A ligand, preventing it from interacting with its cognate receptors, primarily VEGF Receptor-1 (VEGFR-1) and VEGF Receptor-2 (VEGFR-2), which are expressed on the surface of vascular endothelial cells.[13]

The interaction between VEGF-A and its receptors is the critical initiating step in the angiogenic cascade. This signaling pathway promotes endothelial cell proliferation, migration, and survival, leading to the formation of new capillaries—a process essential for tumor growth, invasion, and metastasis.[13] By blocking this interaction, bevacizumab-800CW disrupts the angiogenic signal, effectively "starving" the tumor of the blood supply it needs to thrive. This anti-angiogenic mechanism can also lead to the "normalization" of the characteristically tortuous and leaky tumor vasculature and may decrease the high interstitial pressure within tumors, which can in turn improve the delivery and efficacy of co-administered chemotherapeutic agents.[13] While some recent studies have explored the possibility of direct cytotoxic effects of bevacizumab on tumor cells that express VEGF receptors, the agent's primary and established mechanism of action remains the inhibition of angiogenesis.[14] For the purposes of imaging, this biological action serves to concentrate the agent at sites of active angiogenesis, which are hallmarks of malignant tissue.

2.2 Optical Principle: Near-Infrared Fluorescence for Deep-Tissue Visualization

The second part of the mechanism is physical. After the agent has localized to the tumor via its biological targeting, it serves as a beacon for optical detection. Bevacizumab-800CW can be administered systemically via intravenous injection or, in some investigational settings, orally for endoscopic applications.[2] Following administration, the immunoconjugate circulates throughout the body and preferentially accumulates and is retained in tissues with high expression of its target, VEGF-A—namely, tumors and their associated neovasculature.

During a surgical or endoscopic procedure, an external light source, integrated into the imaging device, illuminates the tissue field with light at the specific excitation wavelength of IRDye 800CW, approximately 775 nm.[17] Upon absorbing a photon of this excitation light, the IRDye 800CW molecule is raised to a higher energy state. It then rapidly returns to its ground state by emitting a photon of light at a slightly longer, lower-energy wavelength, around 795 nm.[17] This emitted light is the fluorescent signal.

A highly sensitive camera, specifically designed to detect light in the NIR spectrum, captures this emitted signal. The imaging system employs a sophisticated set of optical filters to precisely separate the desired fluorescent signal from the much brighter reflected excitation light and from any natural tissue autofluorescence.[17] The processed fluorescence data is then typically displayed as a colorized overlay on the standard, real-time video image of the surgical field, effectively painting the tumor tissue bright green or another designated color for the clinician.[17] This provides an intuitive and immediate visual guide to the location and extent of the tumor. Furthermore, advanced techniques such as multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy can be used not just to see the fluorescence but to quantify it. By measuring tissue optical properties and raw fluorescence, these systems can calculate the intrinsic fluorescence, which is directly proportional to the local concentration of the tracer, enabling objective assessment and the calculation of precise tumor-to-background ratios (TBRs).[17]

This dual mechanism effectively creates a "biological contrast agent." Unlike passive agents such as ICG, which depend on the non-specific and often unreliable Enhanced Permeability and Retention (EPR) effect of leaky tumor vasculature, bevacizumab-800CW adds a critical layer of active molecular targeting.[3] While it also benefits from passive accumulation in tumors, its key advantage is the subsequent high-affinity binding to VEGF-A.[2] This binding acts as a molecular anchor, "trapping" the agent within the tumor microenvironment. Over the hours and days following administration, unbound tracer is gradually cleared from the bloodstream and healthy tissues, which have low levels of VEGF-A.[3] The result, after an optimal time interval (typically 2-4 days for intravenous administration), is a dramatic increase in the signal from the tumor relative to the surrounding normal tissue. This process of targeted retention is the fundamental principle that underlies the agent's superior specificity and its ability to generate the high tumor-to-background ratios essential for precise surgical guidance.

Section 3: Clinical Applications and Performance in Surgical Oncology

The translation of bevacizumab-800CW from a molecular concept to a clinical tool has been explored across a range of oncological applications. Its primary utility lies in providing real-time visual information to clinicians during invasive procedures, with the ultimate goals of improving the completeness of tumor resection, enhancing the detection of early-stage disease, and accurately identifying metastatic spread.

3.1 Fluorescence-Guided Surgery (FGS): Enhancing Real-Time Tumor Delineation

Fluorescence-guided surgery with bevacizumab-800CW is designed to augment the surgeon's senses, providing a real-time molecular map of tumor boundaries that transcends the limitations of preoperative imaging, which can be distorted by patient positioning, and simple tactile feedback.[3]

A central application of this technology is in the assessment of surgical margins. Incomplete resection, where microscopic tumor cells are left behind at the edge of the excised tissue (a "positive margin"), is a primary driver of local cancer recurrence and frequently necessitates re-operation. This is a particularly significant problem in breast-conserving surgery, where positive margin rates can be as high as 20% to 40% worldwide.[6] Clinical studies have shown that bevacizumab-800CW accumulates not only in the bulk of the tumor but also at the microscopic tumor margin, allowing for the ex vivo detection of residual disease that would be invisible to the naked eye.[5] In a foundational Phase I study in breast cancer patients, the agent successfully identified microscopic positive margins in 2 of 20 surgically excised specimens, confirming its potential to provide critical intraoperative information.[7]

The utility of FGS with bevacizumab-800CW extends to complex resections in diseases characterized by widespread, small-volume disease. In peritoneal carcinomatosis, for example, where numerous small tumor nodules are disseminated throughout the abdominal cavity, complete surgical cytoreduction is the most important prognostic factor. Studies in mouse models of ovarian peritoneal carcinomatosis have demonstrated that FGS with bevacizumab-800CW allows surgeons to identify and resect additional nodules missed by conventional visual inspection and palpation, significantly increasing the total tumor burden removed.[3]

3.2 Quantitative Fluorescence Molecular Endoscopy (qFME): Improving Detection of Early-Stage Neoplasia

In the realm of gastroenterology, bevacizumab-800CW is being investigated for use with quantitative fluorescence molecular endoscopy (qFME). This technique employs specialized fiber-optic probes that can be passed through the working channel of an endoscope to both visualize and precisely quantify fluorescent signals from the mucosal surface.[35] This is particularly valuable for the surveillance of premalignant conditions like Barrett's esophagus (BE), a precursor to esophageal adenocarcinoma (EAC).

Standard surveillance protocols for BE, which rely on high-definition white-light endoscopy and narrow-band imaging, are hampered by high miss rates for detecting areas of dysplasia (precancerous changes).[35] An ongoing clinical trial is evaluating an innovative approach using oral administration of bevacizumab-800CW. Preliminary results are highly promising, showing that qFME with the orally delivered tracer detected all endoscopically visible dysplastic lesions in the study cohort. This approach also has the potential to streamline the clinical workflow by eliminating the incubation time required for topically applied tracers, thereby shortening the overall procedure time.[35]

3.3 Efficacy Across Key Oncological Indications

The broad expression of VEGF-A across many tumor types has prompted the investigation of bevacizumab-800CW in a variety of clinical contexts.

3.3.1 Breast Cancer

Breast cancer has been a primary focus for the development of this agent. A key Phase I trial (NCT01508572) established the safety of a 4.5 mg intravenous dose and confirmed tumor-specific uptake in 20 patients with primary invasive breast cancer.[7] Quantitative analysis of excised tissues revealed that tracer levels were significantly higher in the tumor core compared to the tumor margin (

p<0.05) and surrounding healthy tissue (p<0.0001). Furthermore, tracer accumulation showed a strong positive correlation with VEGF-A protein levels (r=0.63,p<0.0002), validating the agent's target specificity.[7] Building on this, the Phase II MARGIN-II study demonstrated a profound clinical impact: the use of bevacizumab-800CW for intraoperative margin assessment during breast-conserving surgery reduced the rate of necessary re-operations by 50%.[41]

3.3.2 Colorectal and Esophageal Cancers

The agent has shown feasibility for detecting gastrointestinal neoplasia. Studies have demonstrated its ability to highlight colorectal adenomas, with quantitative analysis estimating a median tracer concentration of 6.86 nmol/mL in adenomas following a 25 mg intravenous dose.[3] In esophageal cancer, it is being used not only for the detection of early neoplastic lesions in BE but also as a tool to monitor tumor response following neoadjuvant chemoradiotherapy, potentially allowing for more personalized treatment strategies.[35]

3.3.3 Peritoneal Carcinomatosis

In preclinical models of ovarian peritoneal carcinomatosis, FGS with bevacizumab-800CW enhanced the total tumor resection by 8.5% compared to conventional surgery alone. Its performance was particularly noteworthy in the post-neoadjuvant chemotherapy setting—a common and challenging clinical scenario. In these models, bevacizumab-800CW maintained its efficacy, whereas the non-targeted agent ICG failed completely, highlighting the value of molecular targeting in treated tumors.[3]

3.3.4 Central Nervous System Tumors

The application of bevacizumab-800CW in neuro-oncology is an emerging area of research. The Phase I LUMINA trial investigated its use in patients with intracranial meningiomas. The study confirmed the agent's safety and demonstrated high, specific uptake in tumor tissue in ex vivo analyses.[43] The tracer was able to distinguish tumor from healthy dura mater and brain tissue, and could even identify microscopic invasion into the dural tail and adjacent bone. However, a critical finding was that the fluorescent signal could not be detected

in vivo using standard neurosurgical microscopes, pointing to a current limitation in imaging hardware sensitivity.[43] Preclinical studies in meningioma xenograft models have corroborated the agent's high specificity.[24]

3.3.5 Other Investigational Areas

The versatility of the VEGF-A target has led to the exploration of bevacizumab-800CW in other fields. A clinical trial (NCT03913806) has been completed in soft tissue sarcoma to determine the optimal dose for FGS.[44] Other studies have investigated its potential for visualizing neovascularization in ophthalmological conditions like neovascular age-related macular degeneration (nAMD) and for identifying lesions in endometriosis.[45]

3.4 Application in Metastasis and Lymph Node Detection

One of the most significant challenges in surgical oncology is the accurate intraoperative identification of lymph node metastases, which is crucial for correct staging and determining the need for adjuvant therapy.[47] Bevacizumab-800CW is being actively investigated for this purpose. A pilot study (NCT05498051) is currently assessing the feasibility of using peritumoral submucosal injections of the agent for fluorescent sentinel lymph node mapping in patients with colon carcinoma.[49] However, there are potential limitations. Studies using commercially available laparoscopic imaging systems, which are typically optimized for the strong signal of ICG, have suggested that these systems may lack the sensitivity to detect the lower concentrations of bevacizumab-800CW that would be expected to accumulate in metastatic lymph nodes following a systemic intravenous injection. This suggests that successful application for this indication may require either local administration to achieve higher concentrations, the use of higher systemic doses, or the development of more sensitive, next-generation imaging platforms.[47]

The clinical utility of bevacizumab-800CW is not monolithic; its success is highly dependent on the specific clinical context. For surface-level diseases like Barrett's esophagus, an oral administration route is being explored to optimize the clinical workflow, representing a potentially low-barrier application.[35] In breast-conserving surgery, intravenous administration has proven highly effective for

ex vivo margin assessment, with a Phase II trial showing a dramatic 50% reduction in re-operation rates, marking this as a high-impact indication where the technology is already demonstrating its value.[41] Conversely, in deep-cavity procedures like meningioma surgery, while the agent accumulates effectively in the target tissue, current-generation operating microscopes are unable to detect the signal

in vivo, highlighting a hardware-limited application.[43] For challenging tasks like laparoscopic lymph node detection, the feasibility is a complex interplay of administration route (submucosal versus intravenous) and the sensitivity of the imaging hardware.[48] Therefore, the path to widespread clinical adoption of bevacizumab-800CW is not a single trajectory but a portfolio of distinct strategies. Its successful translation into standard practice will necessitate tailored approaches for each indication, requiring careful consideration of not only the agent's inherent properties but also the practicalities of the specific surgical procedure and the capabilities of the available imaging systems.

Section 4: Comparative Assessment Against Standard-of-Care Imaging Agents

The potential clinical value of bevacizumab-800CW can only be fully appreciated through a critical comparison with the imaging agents currently used in fluorescence-guided surgery. The two main comparators are Indocyanine Green (ICG), a non-specific NIR dye, and 5-aminolevulinic acid (5-ALA), a metabolic precursor that induces fluorescence in the visible spectrum.

4.1 Bevacizumab-800CW versus Indocyanine Green (ICG): A Comparison of Specificity and Performance

Indocyanine Green is the most widely used fluorescent agent in surgery, but its mechanism of action is fundamentally different from that of bevacizumab-800CW. ICG is a non-targeted dye that, after intravenous injection, binds to plasma proteins and accumulates passively in tumors through the Enhanced Permeability and Retention (EPR) effect. This phenomenon relies on the fact that tumor blood vessels are often poorly formed and "leaky," allowing the ICG-protein complex to extravasate into the tumor interstitium, while the lack of effective lymphatic drainage in tumors leads to its retention.[36] In contrast, bevacizumab-800CW combines this passive delivery mechanism with a crucial second step of active, high-affinity molecular binding to its target, VEGF-A.[3]

This mechanistic difference has profound implications for imaging specificity and the rate of false positives. Because ICG's accumulation is dependent only on vascular permeability, it cannot distinguish between the leaky vessels of a tumor and the leaky vessels caused by inflammation, infection, or surgical trauma. This lack of specificity frequently leads to high background signals and a significant rate of false-positive findings. In a direct comparison in a mouse model of peritoneal carcinomatosis, the false-positive rate for resected nodules was a mere 3.5% with bevacizumab-800CW, whereas it was 15% with ICG.[3]

The superior performance of bevacizumab-800CW is most dramatically illustrated in the context of post-neoadjuvant chemotherapy surgery. Chemotherapy can alter tumor vasculature and induce inflammation, creating a complex biological environment that severely confounds the non-specific signal of ICG. In the same peritoneal carcinomatosis model, following a course of neoadjuvant chemotherapy, FGS with bevacizumab-800CW still enabled the resection of additional tumor nodules, increasing the total tumor burden removed to 88.7%. Under the same conditions, ICG "did not improve surgery at all," with its signal becoming blurred and clinically useless.[3]

The pharmacokinetic profiles of the two agents also differ significantly. Bevacizumab-800CW, being an antibody conjugate, has a long circulation half-life (measured at 34 hours in mice), while ICG is cleared very rapidly from the bloodstream (half-life of 17 minutes in mice).[3] The long half-life of bevacizumab-800CW necessitates a waiting period of 2-4 days between injection and imaging. While this presents a logistical consideration, it is also a key advantage, as it allows for the thorough clearance of unbound tracer from the blood pool and normal tissues, resulting in a very low background signal and maximizing the tumor-to-background ratio at the time of surgery.

4.2 Bevacizumab-800CW versus 5-Aminolevulinic Acid (5-ALA): Advantages of Targeted Molecular Imaging

5-ALA represents a different class of imaging agent, functioning as a metabolic precursor rather than a targeted probe. After oral administration, 5-ALA is taken up by cells and enters the heme biosynthesis pathway. In many types of cancer cells, particularly high-grade gliomas, enzymatic dysregulation causes the pathway to halt at the intermediate stage of protoporphyrin IX (PpIX), a molecule that is naturally fluorescent.[54] This results in the selective accumulation of an

endogenous fluorophore within the tumor cells. In contrast, bevacizumab-800CW is an exogenous, targeted probe that binds to an extracellular target.

A key physical difference lies in their optical properties. 5-ALA-induced PpIX fluoresces in the visible red part of the spectrum, with an emission maximum around 635 nm.[55] Light at this wavelength has significantly poorer tissue penetration compared to the NIR fluorescence of IRDye 800CW, which emits at approximately 795 nm.[55] This gives NIR probes like bevacizumab-800CW a fundamental physical advantage in visualizing deeper tumor structures or tumor tissue obscured by a thin layer of blood or normal tissue.

In terms of clinical application, 5-ALA is highly effective and has received FDA approval for improving the extent of resection in high-grade gliomas. However, its utility in low-grade gliomas, brain metastases, and other tumor types is less consistent and not as well established.[54] Furthermore, 5-ALA can produce false-positive fluorescence in areas of reactive astrogliosis or other non-neoplastic but metabolically active tissues surrounding a tumor.[60] Antibody-based NIR probes offer a different paradigm. Their specificity is based on the expression of a molecular target (e.g., VEGF-A for bevacizumab-800CW, EGFR for panitumumab-800CW), which may provide a more direct and potentially more broadly applicable method of tumor identification. Indeed, preclinical studies directly comparing the EGFR-targeted panitumumab-800CW to 5-ALA in glioblastoma models found that the antibody conjugate produced a higher TBR, demonstrated higher specificity for tumor core and margin, and had a stronger overall capability to discriminate between malignant and normal brain tissue.[61]

The workflow for these agents also differs. 5-ALA is typically administered orally 3-4 hours prior to surgery, allowing for a same-day procedure.[54] The current standard for intravenously administered bevacizumab-800CW requires a multi-day waiting period, which is a logistical disadvantage. However, the development of oral formulations for endoscopic use suggests that alternative administration strategies may mitigate this issue in the future.[35]

The key differentiating advantage of a targeted agent like bevacizumab-800CW lies in its "signal resilience" within biologically complex environments. A real-world surgical field is often complicated by inflammation, bleeding, and the profound biological changes induced by prior treatments like chemotherapy. Non-specific agents like ICG fail in these scenarios because their mechanism cannot distinguish between the vascular leakiness caused by inflammation and that caused by the tumor itself.[3] Similarly, the metabolic mechanism of 5-ALA can be heterogeneous within a tumor and may be altered in recurrent or previously treated disease.[55] Bevacizumab-800CW's reliance on active binding to a specific molecular target, VEGF-A, makes its signal inherently more robust and resilient to these confounding factors. It is designed to identify the specific molecular signature of angiogenesis, which often persists even after neoadjuvant therapy. This ability to provide a clear, reliable signal in the "messy" context of a complex surgical field, where non-targeted agents falter, is its most critical clinical differentiator.

Feature	Bevacizumab-800CW	Indocyanine Green (ICG)	5-Aminolevulinic Acid (5-ALA)
Mechanism	Active molecular targeting + passive EPR	Passive EPR effect only	Intracellular metabolic conversion
Target	Vascular Endothelial Growth Factor-A (VEGF-A)	Non-specific (leaky vasculature)	Altered heme synthesis pathway
Wavelength	Near-Infrared (~795 nm emission)	Near-Infrared (~830 nm emission)	Visible Red (~635 nm emission)
Specificity	High; target-dependent	Low; relies on vascular permeability	Moderate-High; metabolism-dependent
False Positive Rate	Low (e.g., 3.5% in preclinical model)	High (e.g., 15% in preclinical model)	Moderate (e.g., in reactive tissue)
Performance Post-Chemotherapy	Effective	Ineffective / Fails	Variable / Less studied
Primary Application	Broad (VEGF-A expressing solid tumors)	Perfusion, lymphatics, non-specific tumor	High-grade gliomas

Section 5: Synopsis of Clinical Development and Trial Evidence

The clinical development of bevacizumab-800CW has followed a strategic, parallelized pathway, with numerous early-phase studies conducted across a variety of cancer types to rapidly establish proof-of-concept and identify the most promising clinical applications. This approach has generated a substantial body of evidence regarding the agent's safety, feasibility, and quantitative performance.

5.1 Overview of Key Phase I and Phase II Clinical Trials

The evidence base for bevacizumab-800CW is built upon a series of meticulously designed, though generally small-scale, clinical trials:

• NCT01508572 (Phase I, Breast Cancer): This was a foundational feasibility study involving 20 patients with primary invasive breast cancer. It successfully evaluated the safety, uptake, and localization of a single 4.5 mg intravenous dose. The primary analysis was conducted on surgical specimens to assess tracer accumulation in the tumor, margins, and lymph nodes.[40]
• NCT01972373 (Proof-of-Concept, Rectal Cancer): This study explored the utility of bevacizumab-800CW for "back-table" fluorescence-guided imaging. Freshly resected specimens from patients with locally advanced rectal cancer (LARC) were imaged immediately after surgery to assess the circumferential resection margin (CRM) status, with results correlated to definitive histopathology.[63]
• NCT03913806 (FLASH, Phase I/II, Soft Tissue Sarcoma): This was a dose-escalation study designed to identify the optimal dose of bevacizumab-800CW for intraoperative tumor detection in patients with soft tissue sarcomas. The trial investigated intravenous doses of 10, 25, and 50 mg.[44]
• NCT05745857 (Phase II, Esophageal Cancer): This ongoing trial is a significant step forward, investigating the feasibility and efficacy of oral administration of bevacizumab-800CW (at 4.5 mg and 9 mg doses) for the detection of early esophageal adenocarcinoma in 25 patients with Barrett's esophagus using quantitative fluorescence molecular endoscopy (qFME).[39]
• LUMINA Trial (Phase I, Meningioma): This single-center study assessed the safety, feasibility, and optimal dose (4.5, 10, or 25 mg) of the tracer for molecular fluorescence-guided surgery in patients with intracranial meningiomas, providing the first human data for this application.[43]

5.2 Analysis of Primary Endpoints: Safety, Feasibility, and Dose Optimization

Across these diverse trials, the primary endpoints have consistently focused on establishing the fundamental viability of the agent for clinical use.

• Safety: The safety profile of microdose bevacizumab-800CW has been exemplary. The doses used in imaging studies, ranging from 4.5 mg to 50 mg as a single bolus, are considered "microdoses" and are substantially lower than the weight-based therapeutic doses of bevacizumab.[6] In the Phase I breast cancer and meningioma trials, it was explicitly reported that no tracer-related adverse events occurred.[7] This clinical safety record is further supported by preclinical toxicity studies in mice, which also showed no remarkable findings.[25]
• Feasibility: The collective results of these trials have successfully demonstrated the feasibility of using bevacizumab-800CW for real-time tumor visualization in both surgical and endoscopic settings. The core concept—that targeting the VEGF-A pathway with a fluorescent antibody can effectively highlight malignant tissue—has been validated in human subjects across multiple distinct cancer types.[7]
• Dose Optimization: Identifying the optimal dose that balances a strong signal with minimal background has been a key objective. The LUMINA trial in meningioma patients performed interim analyses and identified 10 mg as the optimal dose, providing the best ex vivo tumor-to-background ratio.[43] The FLASH trial in sarcoma explored a dose range up to 50 mg, and the ongoing esophageal trial is comparing two different oral dose levels to inform future studies.[35]

5.3 Quantitative Efficacy Outcomes: Tumor-to-Background Ratios, Sensitivity, and Specificity

Beyond feasibility, the trials have generated quantitative data on the agent's imaging performance.

• Tumor-to-Background Ratio (TBR): The TBR is a critical metric that quantifies the contrast between the tumor and surrounding healthy tissue. Higher TBRs make it easier for the clinician to delineate the tumor. In the rectal cancer study, bevacizumab-800CW achieved a mean TBR of 4.7 ± 2.5 at a microscopic level.[63] In a preclinical meningioma model, an impressive TBR of 21.1 was reported, indicating very high target-specific accumulation.[24] The selection of the 10 mg optimal dose in the human meningioma trial was based on achieving the best TBR.[43]
• Sensitivity and Specificity: The rectal cancer study provided the first data on diagnostic accuracy. By performing a receiver operating characteristic (ROC) curve analysis on the fluorescence intensities from formalin-fixed tissue slices, researchers determined an optimal cutoff value for defining tissue as malignant. This cutoff yielded a high sensitivity of 96.19% and a specificity of 80.39% for tumor detection.[63]
• Correlation with Target Expression: Crucially, multiple studies have confirmed that the agent's accumulation is directly related to the presence of its molecular target. In the breast cancer trial, a strong and statistically significant positive correlation was found between the fluorescence intensity of bevacizumab-800CW and the level of VEGF-A protein expression in the tumor tissue (r=0.63,p<0.0002).[7] This provides direct evidence that the agent is functioning as a true molecularly targeted probe.

The clinical development strategy for bevacizumab-800CW is distinct from that of a typical therapeutic drug. Rather than a linear progression through Phases I, II, and III in a single disease, the approach has been to establish multiple "beachheads" simultaneously. By conducting numerous, concurrent, small-scale feasibility and dose-finding studies across a wide range of disparate cancers—including breast, rectal, sarcoma, and meningioma—researchers are employing a rapid-screening strategy.[65] The unifying principle is not the organ of origin but the biological target, VEGF-A, which is a common denominator for most solid tumors.[5] This parallelized exploration of a platform technology allows for the efficient identification of the tumor types and clinical settings where the agent can provide the greatest clinical impact. This strategy enables the selection of the most promising "beachhead" applications, such as breast cancer margin assessment where it has already shown a 50% reduction in re-operations, to be advanced into larger, pivotal Phase III trials.

Trial ID / Name	Indication	Phase	# of Patients	Dose(s) Studied	Key Published Results / Status
NCT01508572	Breast Cancer	Phase 1	20	4.5 mg IV	Completed; Confirmed safety and tumor-specific uptake. Detected microscopic positive margins. 7
NCT01972373	Rectal Cancer	Proof-of-Concept	17	4.5 mg IV	Completed; Demonstrated feasibility of back-table CRM evaluation. Sensitivity 96%, Specificity 80%. 63
NCT03913806 (FLASH)	Soft Tissue Sarcoma	Phase 1/2	15	10, 25, 50 mg IV	Completed; Dose-escalation study to find optimal dose for intraoperative detection. 44
NCT05745857	Esophageal Cancer	Phase 2	25	4.5, 9 mg Oral	Active, Not Recruiting; Evaluating oral administration for qFME. Preliminary results show feasibility. 35
LUMINA Trial	Meningioma	Phase 1	9-15	4.5, 10, 25 mg IV	Completed; Confirmed safety. 10 mg identified as optimal dose based on ex vivo TBR. 43

Section 6: Safety, Tolerability, and Pharmacokinetic Profile

A comprehensive assessment of bevacizumab-800CW requires a nuanced understanding of its safety profile, which is fundamentally different from that of its well-known therapeutic counterpart, bevacizumab (Avastin®). This distinction is primarily driven by the vast difference in the administered dose.

6.1 Established Safety Profile of Therapeutic Bevacizumab (Avastin®)

Bevacizumab, when used at therapeutic doses for the treatment of cancer, has a well-characterized and significant toxicity profile. The U.S. Food and Drug Administration (FDA) label for Avastin® includes boxed warnings for serious and sometimes fatal adverse events. These include gastrointestinal perforation, which occurs at an incidence of 0.3% to 3% across clinical studies; the formation of fistulae (abnormal connections between organs); and complications with surgery and wound healing.[30]

Furthermore, therapeutic bevacizumab is associated with a up to five-fold increased risk of severe or fatal hemorrhage, including gastrointestinal bleeding and central nervous system hemorrhage.[66] Both arterial and venous thromboembolic events (blood clots) are also recognized risks.[66] More common, though still serious, adverse events include severe hypertension, with Grade 3-4 hypertension occurring in 5% to 18% of patients, and renal injury leading to proteinuria.[30] This significant toxicity profile is deemed acceptable in the clinical context of treating patients with advanced or metastatic cancer, where the potential benefits of the drug outweigh these substantial risks. These data are based on standard therapeutic dosing regimens, which typically range from 5 to 15 mg/kg of body weight administered every 2-3 weeks.[18]

6.2 Clinical Safety Data for Microdose Bevacizumab-800CW in Imaging Studies

In stark contrast to the therapeutic setting, the doses of bevacizumab-800CW used for diagnostic imaging are classified as "microdoses".[6] The total dose administered in clinical trials has typically ranged from 4.5 mg to 50 mg as a single intravenous bolus. To put this in perspective, a 10 mg microdose administered to a 70 kg patient equates to approximately 0.14 mg/kg. This is more than 35 times lower than a standard 5 mg/kg therapeutic dose.

This dramatic reduction in dose leads to a profoundly different safety profile. Across the entire clinical development program for bevacizumab-800CW, the agent has been shown to be exceptionally safe and well-tolerated. The Phase I feasibility study in 20 breast cancer patients and the Phase I LUMINA trial in meningioma patients both explicitly reported that none of the patients experienced any adverse events related to the administration of the tracer.[7] This remarkable clinical safety record is corroborated by preclinical safety pharmacology studies in mice, which also revealed no remarkable findings after an extended single dose toxicity test.[25] Furthermore,

in vitro studies on cultured human corneal cells found no evidence of cytotoxicity at concentrations up to 5.0 mg/mL, a dose that is 20 times higher than that used for intravitreal applications, further supporting the agent's safety at a cellular level.[74]

The use of the name "bevacizumab" in the agent's nomenclature creates a significant "perception-versus-reality" gap regarding its safety. For clinicians, pharmacists, and institutional review boards, the name is inextricably linked to the serious toxicities of Avastin®. This immediate association can create a perception of high risk that is not supported by the clinical data from microdosing studies. The actual risk demonstrated in trials is negligible, while the perceived risk based on the name is substantial. This cognitive dissonance represents a potential barrier to clinical trial recruitment and eventual adoption. Therefore, it is critical to actively de-couple the safety profile of the therapeutic drug from that of the diagnostic imaging agent through clear communication, emphasizing the quantitative dose difference and the robust safety data from the microdosing trials.

Adverse Event	Incidence with Therapeutic Bevacizumab (e.g., 5-15 mg/kg)	Incidence with Microdose Bevacizumab-800CW (e.g., 4.5-50 mg)
Gastrointestinal Perforation	0.3% - 3% (Serious/Fatal)	Not Observed / 0%
Severe Hemorrhage (Grade 3-4)	0.4% - 7%	Not Observed / 0%
Severe Hypertension (Grade 3-4)	5% - 18%	Not Observed / 0%
Arterial Thromboembolic Events	~5%	Not Observed / 0%
Any Tracer-Related Adverse Event	Common (Epistaxis, Headache, etc.)	Not Observed / 0%

Data synthesized from sources.[7]

6.3 Pharmacokinetics, Biodistribution, and Clearance

As a large protein, bevacizumab-800CW follows the pharmacokinetic profile typical of a monoclonal antibody. It exhibits a long circulation half-life, which was measured to be 34 hours in preclinical mouse models.[3] This prolonged presence in the bloodstream is a key feature of the agent's mechanism. It allows sufficient time for the antibody to extravasate into tumor tissue and bind to its VEGF-A target. The long half-life is also the reason for the necessary delay of 2 to 4 days between intravenous injection and the imaging procedure. This interval is crucial for allowing the unbound tracer to clear from the blood pool and non-target tissues, which is essential for minimizing background fluorescence and maximizing the tumor-to-background ratio.[3] Biodistribution studies conducted on excised tissues have confirmed this pattern, showing the highest concentration of the tracer in tumor tissue, with very low levels of fluorescence detected in healthy tissues such as the brain, skull, and muscle.[24]

Section 7: Regulatory Status and Future Perspectives

The future integration of bevacizumab-800CW into standard clinical practice depends not only on continued successful clinical trials but also on navigating a complex regulatory landscape. It is essential to distinguish between the regulatory status of the therapeutic drug bevacizumab and the investigational status of the diagnostic agent bevacizumab-800CW.

7.1 Regulatory Landscape: Approved Indications for Bevacizumab vs. Investigational Status of Bevacizumab-800CW

Therapeutic bevacizumab, marketed as Avastin® by Genentech, is a fully approved drug with a long history of clinical use. It was first approved by the U.S. FDA in 2004 and the European Medicines Agency (EMA) in 2005.[11] Since then, it and its numerous approved biosimilars—such as Mvasi® (bevacizumab-awwb), Zirabev® (bevacizumab-bvzr), Avzivi® (bevacizumab-tnjn), Jobevne® (bevacizumab-nwgd), and Vegzelma® (bevacizumab-adcd)—have received marketing authorization from major global regulatory bodies, including the FDA, EMA, and Australia's Therapeutic Goods Administration (TGA).[11] The approved indications are extensive and cover a wide range of solid tumors, including metastatic colorectal cancer, non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, ovarian cancer, and hepatocellular carcinoma.[8]

In sharp contrast, bevacizumab-800CW is currently an investigational agent.[46] It does not hold marketing approval from the FDA, EMA, TGA, or any other regulatory agency for any clinical indication. Its use is strictly limited to the context of registered clinical trials.[2] The development of clinical-grade bevacizumab-800CW under Good Manufacturing Practice (GMP) standards was a critical step that enabled these first-in-human studies to proceed.[25]

7.2 Future Directions: Potential for Phase III Trials and Integration into Surgical Workflows

The path forward for bevacizumab-800CW will require further clinical validation and technological advancement. The highly encouraging results from the early-phase studies provide a strong rationale for progressing to larger, pivotal Phase III trials. In particular, the finding from the Phase II MARGIN-II study in breast cancer, which reported a 50% reduction in the rate of re-operations, is a powerful indicator of clinical benefit that warrants confirmation in a larger, randomized controlled trial.[41] Such trials will be necessary to definitively establish that the use of bevacizumab-800CW leads to improved patient outcomes, such as higher rates of complete (R0) resection, lower rates of local recurrence, or improved survival, which would be required to support a regulatory submission for marketing approval.[37]

A parallel and equally critical path of development involves the co-evolution of imaging hardware. The LUMINA trial in meningioma highlighted a key bottleneck: while the tracer accumulated effectively in the tumor, the signal was too weak to be detected in vivo by standard neurosurgical operating microscopes.[43] This indicates that the full potential of targeted NIR probes may only be realized with the development of next-generation camera systems with enhanced sensitivity. Similarly, studies have suggested that current laparoscopic systems, which are optimized for the bright, non-specific signal of ICG, may need to be adapted to reliably detect the more subtle, specific signals from targeted tracers like bevacizumab-800CW, especially for challenging applications like lymph node metastasis detection.[48]

Furthermore, innovation in administration and workflow will be key to broad adoption. The investigation of an oral formulation for use in endoscopy is a prime example of a strategy to simplify the patient pathway and reduce the logistical complexity associated with a multi-day delay after intravenous injection, which could significantly accelerate its integration into clinical practice.[35]

7.3 Broader Implications for the Field of Molecular Imaging and Image-Guided Therapy

The development of bevacizumab-800CW has implications that extend beyond this single agent. It serves as a powerful proof-of-concept for a much broader platform technology of antibody-dye conjugates. The same IRDye 800CW fluorophore can be, and has been, conjugated to other clinically relevant monoclonal antibodies, such as cetuximab (which targets EGFR) and trastuzumab (which targets HER2). This creates the potential for a portfolio of targeted fluorescent tracers that could be selected based on the specific molecular profile of a patient's tumor, paving the way for personalized image-guided surgery.[35]

Beyond its role in surgical guidance, bevacizumab-800CW is also a valuable tool for pharmaceutical development. It provides a non-invasive method to visualize drug distribution and target engagement in real-time, within a living patient. This ability to obtain direct pharmacodynamic data can accelerate the clinical development of new anti-angiogenic therapies and other targeted drugs by providing early, direct evidence of their mechanism of action and confirming that the drug is reaching its intended target.[37]

Ultimately, the success of agents like bevacizumab-800CW signals a fundamental evolution in the practice of surgery. It represents a move away from a purely anatomical approach—"see and cut"—towards a future where surgical decisions are informed by real-time molecular data. This fusion of molecular biology and surgical intervention, or "image-guided therapy," has the potential to enable a level of precision and personalization that is currently unattainable, fundamentally changing how cancer is treated in the operating room.[87]

The regulatory pathway for a product like bevacizumab-800CW is inherently complex, as it occupies a hybrid space between a pharmaceutical drug and a medical device. It is a biological drug product (an immunoconjugate) that is functionally dependent on a specific piece of hardware (a fluorescence camera system) for its clinical effect. This classifies it as a combination product. While the fact that the antibody component, bevacizumab, is already well-characterized and approved may streamline the review of its biological and manufacturing aspects, its clinical efficacy is inextricably linked to the performance of the imaging system used in a trial. A pivotal Phase III study's success or failure could hinge as much on the sensitivity and calibration of the camera as on the properties of the agent itself. This suggests that regulatory approval may need to be sought for the agent-device system as a whole, rather than for the agent in isolation. This complicates the clinical trial design and regulatory strategy, as it necessitates a co-development and potentially a co-submission process with a medical device manufacturer. Navigating this complex regulatory landscape for combination products will be a key strategic challenge for the sponsors of bevacizumab-800CW and will be critical to its ultimate approval and adoption.

Conclusion

In summary, bevacizumab-800CW is a highly promising, target-specific investigational imaging agent that has emerged from a robust preclinical and early-phase clinical development program. The existing body of evidence provides a strong proof-of-concept for its utility in precision oncology.

The agent's primary strengths lie in its elegant design, which combines a highly specific, clinically validated targeting antibody with a high-performance near-infrared fluorophore. This combination has been shown to yield superior specificity and lower false-positive rates compared to non-targeted agents like ICG, particularly in challenging clinical settings such as post-chemotherapy surgery. Furthermore, its administration in sub-therapeutic microdoses has resulted in an excellent safety profile, with no tracer-related adverse events reported in human trials. Its demonstrated ability to improve the detection of early-stage neoplasia, delineate tumor margins with microscopic precision, and identify occult tumor deposits across multiple cancer types underscores its significant clinical potential.

Despite this promise, significant hurdles remain on the path to routine clinical use. The foremost requirements are the successful completion of larger, pivotal Phase III trials to definitively prove a clinical benefit in terms of patient outcomes, and the parallel co-development of optimized, next-generation imaging hardware with sufficient sensitivity to fully leverage the agent's capabilities in vivo. Nevertheless, bevacizumab-800CW stands at the forefront of the rapidly advancing field of molecular imaging. It has the clear potential to become an invaluable tool in the armamentarium of surgical and endoscopic oncology, helping to usher in a new era of molecularly-informed, high-precision cancer therapy.

Works cited

1. www.cancer.gov, accessed September 29, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bevacizumab-irdye-800cw#:~:text=An%20immunoconjugate%20and%20a%20fluorescent,used%20for%20VEGF%2Dspecific%20tumor
2. Definition of bevacizumab-IRDye 800CW - NCI Drug Dictionary, accessed September 29, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bevacizumab-irdye-800cw
3. Tumor-Specific Imaging with Angiostamp800 or Bevacizumab-IRDye 800CW Improves Fluorescence-Guided Surgery over Indocyanine Green in Peritoneal Carcinomatosis - MDPI, accessed September 29, 2025, https://www.mdpi.com/2227-9059/10/5/1059
4. Tumor-Specific Imaging with Angiostamp800 or Bevacizumab ..., accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/35625796/
5. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer - CORE, accessed September 29, 2025, https://core.ac.uk/download/pdf/232501371.pdf
6. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer - AACR Journals, accessed September 29, 2025, https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-16-0437/2109921/1078-0432_ccr-16-0437v2.pdf
7. Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study - AACR Journals, accessed September 29, 2025, https://aacrjournals.org/clincancerres/article/23/11/2730/79646/Tumor-Specific-Uptake-of-Fluorescent-Bevacizumab
8. Definition of bevacizumab - NCI Drug Dictionary, accessed September 29, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bevacizumab
9. Bevacizumab B8800H28 - Evidentic GmbH, accessed September 29, 2025, https://evidentic.com/products/bevacizumab-b8800h28/
10. Bevacizumab (anti-VEGF) VEGFR inhibitor | Read Reviews & Product Use Citations, accessed September 29, 2025, https://www.selleckchem.com/products/bevacizumab.html
11. bevacizumab | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 29, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=6771
12. 64Cu-1,4,7-Triazacyclononane-1,4,7-triacetic acid-p-isothiocyanatobenzyl-bevacizumab-IRDye 800CW - NCBI, accessed September 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK127545/
13. What is the mechanism of action of Bevacizumab? - Patsnap Synapse, accessed September 29, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-bevacizumab
14. Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/6652652_Mechanisms_of_Action_of_Bevacizumab_as_a_Component_of_Therapy_for_Metastatic_Colorectal_Cancer
15. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/17145519/
16. Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer - AACR Journals, accessed September 29, 2025, https://aacrjournals.org/clincancerres/article-pdf/23/11/2730/2301193/2730.pdf
17. bevacizumab-800CW Near-infrared fluorescence molecular endoscopy (NIR-FME), accessed September 29, 2025, https://www.thno.org/v08/p1458/thnov08p1458s1.pdf
18. Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer - DSpace, accessed September 29, 2025, https://dspace.library.uu.nl/bitstream/handle/1874/359318/Tumor.pdf?sequence=1
19. 5' IRDye® 800CW (NHS Ester) modification | IDT - Integrated DNA Technologies, accessed September 29, 2025, https://www.idtdna.com/site/catalog/modifications/product/3037
20. IRDye® 800CW, NHS ester Supplier | CAS 956579-01-4 | Tocris Bioscience, accessed September 29, 2025, https://www.tocris.com/products/irdye-800cw-nhs-ester_8881
21. IRDye® 800CW, DBCO Supplier | CAS 1373928-39-2 | Tocris Bioscience, accessed September 29, 2025, https://www.tocris.com/products/irdye-800cw-dbco_8879
22. IRDye 800CW NHS Ester will Label Primary and Secondary Amines. - Shop - LICORbio™, accessed September 29, 2025, https://www.licorbio.com/reagents/irdye-800cw-nhs-ester
23. LI COR BIOTECH LLC IRDye 800CW NHS Ester (0.5 mg) - Fisher Scientific, accessed September 29, 2025, https://www.fishersci.com/shop/products/irdye-800cw-nhs-ester-0-5mg/NC9690013
24. (PDF) Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/364927107_Feasibility_of_bevacizumab-IRDye800CW_as_a_tracer_for_fluorescence-guided_meningioma_surgery
25. Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/27179587/
26. Bevacizumab - StatPearls - NCBI Bookshelf, accessed September 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK482126/
27. Bevacizumab - PMC, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3228024/
28. pmc.ncbi.nlm.nih.gov, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3228024/#:~:text=Bevacizumab%20acts%20by%20selectively%20binding,blood%20supply%20to%20tumor%20tissues.
29. What is the mechanism of Bevacizumab? - Patsnap Synapse, accessed September 29, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-bevacizumab
30. Pharmacology of Bevacizumab (Avastin); Overview, Pharmacokinetics, Mechanism of action, Uses, Effect - YouTube, accessed September 29, 2025, https://www.youtube.com/watch?v=pv-xMtTJbGk
31. Direct antitumor activity of bevacizumab: an overlooked mechanism? - Frontiers, accessed September 29, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1394878/full
32. Avastin® (bevacizumab) Proposed MOA | MCRC Treatment, accessed September 29, 2025, https://www.avastin.com/hcp/mcrc/proposed-moa.html
33. How Avastin® (bevacizumab) works for metastatic colorectal cancer (mCRC), accessed September 29, 2025, https://www.avastin.com/patient/mcrc/about/how-avastin-works.html
34. How Avastin (Bevacizumab) Targeted Therapy Treats Advanced Cancer - YouTube, accessed September 29, 2025, https://www.youtube.com/watch?v=tyecH9Mi194
35. Oral administration of bevacizumab-800CW and cetuximab-800CW ..., accessed September 29, 2025, https://jnm.snmjournals.org/content/65/supplement_2/242111
36. Visible concentrations of bevacizumab-800CW and ICG with four... - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Visible-concentrations-of-bevacizumab-800CW-and-ICG-with-four-laparoscopes-using-varying_fig2_370452028
37. Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/28119364/
38. Angiostamp800 and Bevacizumab-IRDye 800CW improved fluorescence-guided... | Download Scientific Diagram - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Angiostamp800-and-Bevacizumab-IRDye-800CW-improved-fluorescence-guided-surgery-for_fig2_360351797
39. Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas | Clinical Research Trial Listing - CenterWatch, accessed September 29, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT05745857/oral-bevacizumab-800cw-and-cetuximab-800cw-administration-to-detect-early-esophageal-adenocarcinomas
40. Trial | NCT01508572 - Clinical Drug Experience Knowledgebase, accessed September 29, 2025, https://cdek.crib.liu.edu/trial/NCT01508572/
41. Abstract PS1-21: Molecular fluorescence-guided surgery using Beva800 for the assessment of tumor margins during breast conserving surgery of patients with primary breast cancer (MARGIN-II) | Semantic Scholar, accessed September 29, 2025, https://www.semanticscholar.org/paper/e001b5f128b21c8785475c44481c1737ed8995f3
42. Bevacizumab-800CW fluorescence and optical properties. A - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Bevacizumab-800CW-fluorescence-and-optical-properties-A-Bevacizumab-800CW-fluorescence_fig4_381007304
43. Bevacizumab-IRDye800CW for tumor detection in fluorescence-guided meningioma surgery (LUMINA trial): a single-center phase I study - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/38968617/
44. Study Details | FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CW | ClinicalTrials.gov, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT03913806
45. Comparison of fluorescence molecular imaging using bevacizumab-800CW with fluorescein angiography and OCT in neovascular Age-related Macular Degeneration (nAMD) | IOVS, accessed September 29, 2025, https://iovs.arvojournals.org/article.aspx?articleid=2803810
46. Bevacizumab-800CW in Endometriosis - Clinical Trials Registry - ICH GCP, accessed September 29, 2025, https://ichgcp.net/clinical-trials-registry/NCT02975219
47. Visibility of bevacizumab-800CW with four laparoscopes correlated with... - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Visibility-of-bevacizumab-800CW-with-four-laparoscopes-correlated-with-TBR-SNR-and-CNR_fig4_370452028
48. Detection of Tumour-Targeted IRDye800CW Tracer with Commercially Available Laparoscopic Surgical Systems - PMC - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10178288/
49. Study Details | Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW. | ClinicalTrials.gov, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT05498051
50. Detection of Tumour-Targeted IRDye800CW Tracer with Commercially Available Laparoscopic Surgical Systems - MDPI, accessed September 29, 2025, https://www.mdpi.com/2075-4418/13/9/1591
51. Ex vivo quantification of bevacizumab–IRDye800CW and VEGF-A in whole... - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Ex-vivo-quantification-of-bevacizumab-IRDye800CW-and-VEGF-A-in-whole-blood-and-tissue_fig3_309892152
52. Angiostamp800 and Bevacizumab-IRDye 800CW showed fewer false-positive... | Download Scientific Diagram - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Angiostamp800-and-Bevacizumab-IRDye-800CW-showed-fewer-false-positive-fluorescent-signals_fig5_360351797
53. Angiostamp800 and Bevacizumab-IRDye 800CW, but not ICG, improved... - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Angiostamp800-and-Bevacizumab-IRDye-800CW-but-not-ICG-improved-fluorescence-guided_fig4_360351797
54. Comparative Analysis of 5-ALA and Fluorescent Techniques in High-Grade Glioma Treatment - MDPI, accessed September 29, 2025, https://www.mdpi.com/2227-9059/13/5/1161
55. Fluorescence-Guided Surgery in Glioblastoma: 5-ALA, SF or Both? Differences between Fluorescent Dyes in 99 Consecutive Cases - MDPI, accessed September 29, 2025, https://www.mdpi.com/2076-3425/12/5/555
56. Current and Future Applications of 5-Aminolevulinic Acid in Neurosurgical Oncology - MDPI, accessed September 29, 2025, https://www.mdpi.com/2072-6694/17/8/1332
57. 5-ALA induced PpIX fluorescence spectroscopy in neurosurgery: a review - Frontiers, accessed September 29, 2025, https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2024.1310282/full
58. 5-ALA fluorescence on tumors different from malignant gliomas. Review of the literature and our experience | Request PDF - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/338724001_5-ALA_fluorescence_on_tumors_different_from_malignant_gliomas_Review_of_the_literature_and_our_experience
59. Comparative Analysis of 5-ALA and Fluorescent Techniques in High-Grade Glioma Treatment - PMC - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12108851/
60. What is the Surgical Benefit of Utilizing 5-ALA for Fluorescence-Guided Surgery of Malignant Gliomas? - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4615466/
61. Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7483817/
62. Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme - AACR Journals, accessed September 29, 2025, https://aacrjournals.org/mct/article-pdf/19/9/1922/1865866/1922.pdf
63. Back-Table Fluorescence-Guided Imaging for Circumferential ..., accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/31628218/
64. Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer | Journal of Nuclear Medicine, accessed September 29, 2025, https://jnm.snmjournals.org/content/61/5/655
65. (PDF) Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/355250824_Detection_by_fluorescence_of_pituitary_neuroendocrine_tumour_PitNET_tissue_during_endoscopic_transsphenoidal_surgery_using_bevacizumab-800CW_DEPARTURE_trial_study_protocol_for_a_non-randomised_non-bli
66. Avastin® (bevacizumab) Important Safety Information, accessed September 29, 2025, https://www.avastin.com/hcp/safety.html
67. Avastin® (bevacizumab) Adverse Events | MCRC Treatment, accessed September 29, 2025, https://www.avastin.com/hcp/mcrc/safety.html
68. Avastin® (bevacizumab) Clinical Trials | MCRC Treatment, accessed September 29, 2025, https://www.avastin.com/hcp/mcrc/efficacy-data.html
69. Avastin® (bevacizumab) Efficacy, Safety, Dosing & Prescribing Information, accessed September 29, 2025, https://www.avastin.com/hcp.html
70. Adverse events associated with bevacizumab | Download Table - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/Adverse-events-associated-with-bevacizumab_tbl1_50305010
71. Bevacizumab (intravenous route) - Side effects & uses - Mayo Clinic, accessed September 29, 2025, https://www.mayoclinic.org/drugs-supplements/bevacizumab-intravenous-route/description/drg-20068373
72. Avastin® (bevacizumab) Adverse Events | mRCC Treatment, accessed September 29, 2025, https://www.avastin.com/hcp/mrcc/safety.html
73. Bevacizumab-induced Serious Side-Effects: A Review of the French Pharmacovigilance Database - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/22349162/
74. Safety profile of bevacizumab on cultured human corneal cells - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/17721300/
75. Sandoz/Bio-Thera's Avzivi® Bevacizumab Biosimilar FDA Approved - Pearce IP, accessed September 29, 2025, https://www.pearceip.law/2023/12/08/approval-alert-sandoz-bio-theras-avzivi-bevacizumab-biosimilar-fda-approved/
76. European Medicines Agency (EMA) Approves Bio-Thera Solutions' BAT1706 (Avzivi®, bevacizumab), a biosimilar referencing Avastin, accessed September 29, 2025, https://www.bio-thera.com/plus/view.php?aid=1028
77. FDA Approves Bevacizumab Biosimilar for Various Cancer Types | Pharmacy Times, accessed September 29, 2025, https://www.pharmacytimes.com/view/fda-approves-bevacizumab-biosimilar-for-various-cancer-types
78. FDA Approves Biocon Biologics' Bevacizumab Biosimilar | Insights & Resources - Goodwin, accessed September 29, 2025, https://www.goodwinlaw.com/en/insights/blogs/2025/04/fda-approves-biocon-biologics-bevacizumab-biosimilar
79. FDA Approves Bevacizumab-adcd Biosimilar in 6 Cancer Types - CancerNetwork, accessed September 29, 2025, https://www.cancernetwork.com/view/fda-approves-bevacizumab-adcd-biosimilar-in-6-cancer-types
80. FDA Approves Bevacizumab Biosimilar - The ASCO Post, accessed September 29, 2025, https://ascopost.com/news/april-2025/fda-approves-bevacizumab-biosimilar/
81. Bevacizumab Biosimilar Approved for Intravenous Use in Solid Tumors - CancerNetwork, accessed September 29, 2025, https://www.cancernetwork.com/view/bevacizumab-biosimilar-approved-for-intravenous-use-in-solid-tumors
82. Onbevzi (bevacizumab) - Therapeutic Goods Administration (TGA), accessed September 29, 2025, https://www.tga.gov.au/resources/auspmd/onbevzi-bevacizumab
83. FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma, accessed September 29, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma
84. CENTER FOR DRUG EVALUATION AND RESEARCH - accessdata.fda.gov, accessed September 29, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/125085Orig1s332.pdf
85. Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW | ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT05359874
86. Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10763108/
87. What is the future role of bevacizumab in pretreated cervical cancer? - YouTube, accessed September 29, 2025, https://www.youtube.com/watch?v=0YiAKUCTeCo
88. Mapping Progress in Pancreatic Cancer Surgery: Looking to the Future | OncLive, accessed September 29, 2025, https://www.onclive.com/view/mapping-progress-in-pancreatic-cancer-surgery-looking-to-the-future